MDGL Stock: Price, Earnings History and SEC Filings
Madrigal Pharmaceuticals, Inc. (MDGL) last traded at $430.36, down 0.31% on the latest session and down 14.6% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-1.99 against an analyst estimate of $-2.55, a beat of 22.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
MDGL earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 30, 2026 | $-1.99 | $-2.55 | +21.96% |
| Mar 2026 | May 6, 2026 | $-3.25 | $-3.61 | +9.97% |
| Dec 2025 | Feb 19, 2026 | $-2.57 | $0.04 | -6525.00% |
| Sep 2025 | Nov 4, 2025 | $-5.08 | $-1.98 | -156.57% |
MDGL beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
How MDGL reacts to earnings
Across its last 8 earnings releases, MDGL moved 9.0% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-07-30 | Before open | -9.83% |
| 2026-05-06 | Before open | +7.42% |
| 2026-02-19 | Before open | -11.11% |
| 2025-11-04 | Before open | +7.83% |
| 2025-08-05 | Before open | +8.59% |
| 2025-05-01 | Before open | -1.86% |
| 2025-02-26 | Before open | +14.99% |
| 2025-01-13 | Before open | -10.39% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
MDGL financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $958M | -$288M | -$190M | -30.1% | $-12.85 |
| 2024 | $180M | -$466M | -$457M | -258.6% | $-21.90 |
| 2023 | $0 | -$374M | -$326M | – | $-19.99 |
| 2022 | $0 | -$295M | -$225M | – | $-17.23 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for MDGL
- 8-K · Aug 12, 2026Officer or director change, Regulation FD disclosure, Financial statements and exhibits
- 10-Q · Jul 30, 2026
- 8-K · Jul 30, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 17, 2026Officer or director change, Shareholder vote, Financial statements and exhibits
- 10-Q · May 6, 2026
- 8-K · May 6, 2026Results of operations, Financial statements and exhibits
- 8-K · Apr 28, 2026Officer or director change
- DEF 14A · Apr 28, 2026
- 10-K · Feb 19, 2026
- 8-K · Feb 19, 2026Results of operations, Financial statements and exhibits
Insider filing activity
MDGL insiders filed 3 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
MDGL news
- Inventiva (IVA) vs. CRSP and MDGL: Can Lanifibranor’s Phase 3 Trial Unlock 62% Upside?Oct 28, 2026 · finance.yahoo.com
- Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out forOct 28, 2026 · finance.yahoo.com
- Will Madrigal (MDGL) Report Negative Earnings Next Week? What You Should KnowOct 27, 2026 · finance.yahoo.com
- Madrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASHOct 27, 2026 · finance.yahoo.com
- Analysts Estimate Alps Alpine Co Ltd. - Unsponsored ADR (APELY) to Report a Decline in Earnings: What to Look Out forOct 27, 2026 · msn.com
- Can Corcept Therapeutics Stock Rally 40% After This Dip?Oct 26, 2026 · trefis.com
- Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026Oct 20, 2026 · finance.yahoo.com
- BridgeBio, Madrigal, Cytokinetics Trade Lower Ahead of Q3 Results Amid Lack of Near-Term Catalysts, BofA SaysOct 19, 2026 · finance.yahoo.com
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. (MDGL) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.